AbGn-107 will be administered every 14 days (Q2W regimen) or 28 days. Update Monoclonal Antibody (mAb) IgG1 AG7 targeting CD71 Linker Cleavable linker Drug/Payload Tubulin inhibitor DM4 Cleavage Mechanism/MOA Immunomodulators Clinical Trials A Study of AbGn-107 in Patients With Gastric, ...
AbGn-107 is an ADC. The idea here is to take a very potent chemotherapy that is known [within the field] and is something that we can't actually give to patients intravenously because it's too toxic. [Instead], we bind it to an antibody that will bring that drug directly to the can...
抗HUMAN CD71/TFRC (ABGN-107) 单克隆抗体 CBNumber: CB112783334 分子式: 分子量: 0 MOL File: Mol file 化学性质安全信息用途供应商0 抗HUMAN CD71/TFRC (ABGN-107) 单克隆抗体化学性质 安全信息 抗HUMAN CD71/TFRC (ABGN-107) 单克隆抗体性质、用途与生产工艺 ...
KRAS G12C抑制剂AMG 510和抗体药物偶联物(ADC)AbGn-107分别在KRAS G12C突变结直肠癌(CRC)和胃肠道(GI)癌症患者的早期研究中证明其有效性和耐受性。 在一项人类Ⅰ期CodeBreak 100研究中,研究者对AMG 510在患有KRAS G12C突变的晚期实体瘤患者中进行了评估,其中包括一组经过大量预处理的大肠癌患者(n=42)。中...